Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Interest rates are back in the spotlight with a Federal Reserve interest rate decis...
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen...
DUBLIN , March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA. Matt Young , executive vice president and chief...
Jazz Pharmaceuticals, Inc. (JAZZ) Q4 2018 Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Katherine Littrell - Head of IR Bruce Cozadd - Chairman and Chief Executive Officer Matthew Young - Executive Vice President and Chief Financial Officer Daniel...
The following slide deck was published by Jazz Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Gainers: TNDM +14.6% . JAZZ +9.1% . FTR +11.3% . DF +9.0% . PANW +8.0% . More news on: Tandem Diabetes Care, Inc., Jazz Pharmaceuticals, Inc., Frontier Communications Corporation, Stocks on the move, Read more ...
Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q4 results ($M): Revenues: 476.5 (+9.2%). More news on: Jazz Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q4 Non-GAAP EPS of $3.64 beats by $0.62 ; GAAP EPS of $2.64 beats by $0.65 . Revenue of $476.5M (+9.2% Y/Y) beats by $16.83M . Shares +9.8% . Press Release More news on: Jazz Pharmaceuticals, Inc., Earnings news and commentary, Stocks on th...
Total Revenues Increased 17% to $1.9 Billion in 2018 GAAP Diluted EPS of $7.30 ; Adjusted Diluted EPS of $13.70 Launched Vyxeos for AML in the EU and Initiated Broad Development Program Received U.S. Approval of Xyrem for Pediatric Narcolepsy Submitted the MAA to EMA fo...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...